Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Guangzhou Jiayin Biotech Ltd

Clinical trials sponsored by Guangzhou Jiayin Biotech Ltd, explained in plain language.

Not yet recruiting 1

One-Shot gene therapy could free patients from monthly eye injections

Disease control Not yet recruiting

This early-stage study is testing a new one-time gene therapy called EXG202 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can safely deliver a vision-protecting protein long-term, potentially replacing the…

Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Jiayin Biotech Ltd • Aim: Disease control

Last updated Mar 30, 2026 14:35 UTC